Dentsply Sirona Reports Third Quarter 2026
Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29
Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity
Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30
DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.
"We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth."
Gross profit and adjusted EBITDA include a $39 million benefit from the refinement of our estimate to eliminate unrealized profit in inventory. The adjustment reduces the reported net loss and increases adjusted net income by approximately $30 million. This amount represents the cumulative impact of the revised estimate and equivalent impacts are not expected in future.
(in millions, except per share amount Q3 26 Q3 25 YoY and percentages) Net Sales $836 $904 -7.6% Gross Profit $443 $441 0.3% Gross Margin 52.9% 48.8% Net Loss Attributable to Dentsply Sirona -$2 -$427 NM Diluted Loss Per Share1 -$0.01 -$2.14 NM
(in millions, except per share amount Q3 26 Q3 25 YoY and percentages) Constant Currency Sales -7.0% Adjusted EBITDA $146 $167 -13.3% Adjusted EBITDA Margin 17.3% 18.4% Adjusted EPS $0.29 $0.42 -29.4%
[1] Weighted-average shares outstanding used to calculate diluted loss per share for the third quarter of 2026 excludes potential dilutive common shares.
Operating cash flow in the third quarter of 2026 was $32 million, compared to $79 million in the third quarter of 2025, primarily driven by unfavorable working capital. Free cash flow, a Non-GAAP measure, in the third quarter of 2026 was $0 million compared to $40 million in the third quarter of 2025. In the third quarter of 2026, the Company repurchased 1.2 million shares of its common stock for a total of approximately $13 million, resulting in a total of $25 million returned to stockholders through share repurchases in the first nine months of 2026. The Company had $195 million of cash and cash equivalents as of September 30, 2026.
The Company is updating its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.
Without unreasonable effort, we are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.
Dentsply Sirona's management team will host an investor conference call and live webcast on November 5, 2026 at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.
For those planning to participate on the call, please register at http://register-conf.media- server.com/register/BI087bbe14635a47a484497a4e4376efc9. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.
Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products. Contact Information:
Vice President, Public Relations, Corporate Communications & Brand [email protected]
All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any result, expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward- looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets: Cash and cash equivalents $ 195 $ 326 Accounts and notes 605 688 receivable-trade, net Inventories, net 707 642 Prepaid expenses and other current 471 367 assets Total Current Assets 1,978 2,023 Property, plant, and 845 861 equipment, net Operating lease 126 139 right-of-use assets, net Identifiable intangible 815 974 assets, net Goodwill 1,136 1,148 Other noncurrent assets 290 284 Total Assets $ 5,190 $ 5,429 Liabilities and Equity Current Liabilities: Accounts payable $ 238 $ 300 Accrued liabilities 706 700 Income taxes payable 58 30 Notes payable and current portion of 215 313 long-term debt Total Current Liabilities 1,217 1,343 Long-term debt 1,985 2,015 Operating lease liabilities 87 93 Deferred income taxes 74 94 Other noncurrent 473 544 liabilities Total Liabilities 3,836 4,089 Total Equity 1,354 1,340 Total Liabilities and $ 5,190 $ 5,429 Equity
Nine Months Ended Cash flows from operating September 30, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income (loss) $ 23 $ -453 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation 110 104 Amortization of intangible 136 155 assets Goodwill asset impairment — 409 Indefinite-lived intangible asset 3 88 impairment Deferred income taxes -50 44 Stock-based compensation 25 25 expense Other non-cash expense 3 13 (Gain) loss on disposal of -7 — assets Changes in operating assets and liabilities: Accounts and notes 67 -56 receivable-trade, net Inventories, net -78 -61 Prepaid expenses and other current -5 -10 assets Other noncurrent assets -2 — Accounts payable -21 -9 Accrued liabilities -61 -66 Income taxes 30 -45 Other noncurrent -2 -4 liabilities Net cash provided by operating 171 134 activities Cash flows from investing activities: Capital expenditures -128 -90 Cash received on — 10 derivative contracts Cash paid on derivative — -9 contracts Net investment hedge -17 — settlements Proceeds from sale of property, plant, 4 — and equipment Other investing activities 6 2 Net cash used in investing -135 -87 activities Cash flows from financing activities: Cash paid for treasury -25 — stock Proceeds from 364-day — 435 bridge loan Repayment of 364-day — -435 bridge loan Proceeds (repayments) on short-term 130 -416 borrowings, net Cash dividends paid -32 -96 Proceeds from long-term — 551 borrowings Repayments on long-term -225 -3 borrowings Cash paid for deferred — -13 financing costs Other financing -6 -4 activities, net Net cash (used in) provided by financing -158 19 activities Effect of exchange rate changes on cash -9 25 and cash equivalents Net (decrease) increase in cash and cash -131 91 equivalents Cash and cash equivalents at beginning 326 272 of period Cash and cash equivalents at end of $ 195 $ 363 period Supplemental disclosures of cash flow information: Interest paid, net of amounts $ 78 $ 65 capitalized Non-cash investing activities: Property, plant and equipment in $ 37 $ 25 accounts payable at end of period Exchange of inventory for naming and $ — $ 14 other rights
Supplemental Information – Reconciliation of GAAP to Non-GAAP Financial Measures We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States ("GAAP") with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; adjusted gross profit as a percent of net sales ("Adjusted Gross Margin"); adjusted operating income; adjusted operating income as a percent of net sales ("Adjusted Operating Margin"); adjusted earnings before interest expense, income taxes, depreciation and amortization ("Adjusted EBITDA"); Adjusted EBITDA as a percent of net sales ("Adjusted EBITDA Margin"); adjusted net income (loss); adjusted earnings (loss) per diluted share ("Adjusted EPS"); and Free Cash Flow. These non-GAAP financial measures are used by the Company to measure its performance and management believes these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.
• Constant Currency: reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.
• Adjusted Operating Income and Margin: Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales.
◦ Business combination-related costs : costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.
◦ Restructuring-related charges and other costs : costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.
◦ Goodwill and intangible asset impairments : include charges related to goodwill and intangible asset impairments.
◦ Amortization of purchased intangible assets : includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.
◦ Fair value and credit risk adjustments : include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments.
• Adjusted Gross Profit and Margin: gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales. Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.
• Adjusted Net Income (Loss): net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above and the related income tax impacts of those
items, as well as the tax effects of certain significant and discrete tax adjustments, including benefits and provisions related to changes in realization of deferred tax assets and tax credit carryforwards, as well as other events that affect comparability and are not core to our underlying operational performance.
• Adjusted EBITDA and Margin: in addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.
• Adjusted Earnings (Loss) Per Diluted Share: computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.
• Free Cash Flow: net cash provided by operating activities minus capital expenditures during the same period.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period. The weighted-average diluted shares outstanding used in the calculation of adjusted net loss per diluted share excludes potential dilutive common shares.
(unaudited) Beginning in fiscal year 2026, the Company updated its definition of Adjusted Net Income (Loss), a non-GAAP financial measure, to include adjustments for certain significant and discrete tax items, including benefits and provisions related to changes in the realization of deferred tax assets and tax credit carryforwards, as well as other tax‑related items that affect comparability and are not considered part of the Company's core operational performance. Prior- period information below has been updated to conform to current period presentation. A reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP financial statements items are as follows:
(unaudited) Reconciliations of reported net loss attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:
Three Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net loss attributable to $ -2 $ -427 Dentsply Sirona Interest expense, net 25 23 Provision for income taxes 29 198 Depreciation(1) 36 36 Amortization of intangible 46 56 assets Restructuring-related charges and other 10 17 costs Goodwill and intangible asset 3 262 impairments Business combination-related costs and — 2 fair value adjustments Fair value and credit risk -1 — adjustments Adjusted EBITDA $ 146 $ 167 Net sales $ 836 $ 904 Adjusted EBITDA margin 17.3 % 18.4 %
(1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.
A reconciliation of free cash flow for the three months ended September 30, 2026 and 2025 is as follows:
Full text with the tables
Dentsply Sirona Reports Third Quarter 2026
Results
News Summary
•
Q3 2026 net sales of $836 million
•
Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01)
•
Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%,
adjusted EPS of $0.29
•
Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported
growth; completed the U.S. Surity
TM
portfolio with the launch of the Surity
TM
Urinary Management System
•
Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted
EPS of $1.20 to $1.30
Charlotte, N.C., November 5, 2026 -
DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today
announced its financial results for the third quarter of 2026.
"We continued to make progress on our Return-to-Growth Action Plan in the third
quarter despite challenging industry-wide conditions," said Dan Scavilla,
President and Chief Executive Officer of Dentsply Sirona. "We are seeing
encouraging signs of progress, including record quarterly sales for Wellspect
Healthcare, progress in priority areas of implants and endodontics, and broader
customer access through our expanded U.S. dealer network. Building on the
investments we began in the first half, our focus is now on execution, putting
our sales force, clinical education and innovation capabilities to work to drive
consistent performance and sustainable growth."
Q3 2026 Summary Results (Reported)
Gross profit and adjusted EBITDA include a $39 million benefit from the
refinement of our estimate to eliminate unrealized profit in inventory. The
adjustment reduces the reported net loss and increases adjusted net income by
approximately $30 million. This amount represents the cumulative impact of the
revised estimate and equivalent impacts are not expected in future.
(in millions, except per share amount Q3 26 Q3 25 YoY
and percentages)
Net Sales $836 $904 -7.6%
Gross Profit $443 $441 0.3%
Gross Margin 52.9% 48.8%
Net Loss Attributable to Dentsply Sirona -$2 -$427 NM
Diluted Loss Per Share1 -$0.01 -$2.14 NM
Q3 2026 Summary Results (Non-GAAP)
(in millions, except per share amount Q3 26 Q3 25 YoY
and percentages)
Constant Currency Sales -7.0%
Adjusted EBITDA $146 $167 -13.3%
Adjusted EBITDA Margin 17.3% 18.4%
Adjusted EPS $0.29 $0.42 -29.4%
NM - not meaningful
Percentages are based on actual values and may not reconcile due to rounding.
[1] Weighted-average shares outstanding used to calculate diluted loss per share
for the third quarter of 2026 excludes potential dilutive common shares.
Q3 2026 Results by Region and Segment (Reported and Non-GAAP)
(in millions, except percentages)
Pe…
Ch…
Th…
Mo…
En…
Se…
N… 30,
S… 20…
by vs.
S… 20…
──────────────────────────────────────────────────────────────────────────────
Am… EM… AP…
20… 20… As C… As C… As C… As C…
Re… C… Re… C… Re… C… Re… C…
C…
T… $ 2… $ 2… (1… (… (2… (… (5… (… (4… (…
S…
E…
D… 3… 3… (4… (… (0… (… (7… (… (4… (…
S…
O…
a… 1… 2… (1… (… (2… (… (1… (… (7… (…
I…
S…
W… 92 83 10… 1… 77… 7… 1.… 2… (1… 4…
H…
T… $ 8… $ 9… (7… (… (9… (… (6… (… (5… (…
(…
C…
c…
s…
a…
a
N…
m…
in
w…
t…
r…
n…
s…
a…
a…
f…
t…
i…
of
f…
c…
c…
w…
is
c…
by
t…
c…
p…
n…
s…
u…
t…
c…
p…
p…
f…
c…
e…
r…
T…
f…
c…
i…
is
t…
o…
r…
i…
b…
as
r…
a…
c…
c…
s…
Cash Flow and Liquidity
Operating cash flow in the third quarter of 2026 was $32 million, compared to
$79 million in the third quarter of 2025, primarily driven by unfavorable
working capital. Free cash flow, a Non-GAAP measure, in the third quarter of
2026 was $0 million compared to $40 million in the third quarter of 2025. In the
third quarter of 2026, the Company repurchased 1.2 million shares of its common
stock for a total of approximately $13 million, resulting in a total of $25
million returned to stockholders through share repurchases in the first nine
months of 2026. The Company had $195 million of cash and cash equivalents as of
September 30, 2026.
2026 Outlook
The Company is updating its 2026 outlook to approximately $3.5 billion in net
sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit
from tariff refunds.
Without unreasonable effort, we are unable to present a quantitative
reconciliation of our expected earnings per diluted share to expected adjusted
earnings per diluted share as we are unable to predict with reasonable
certainty, items which may include, but are not limited to, restructuring
charges, transformation-related costs, impairment charges, certain tax
adjustments, and other significant items. The financial impact of these items is
uncertain and is dependent on various factors, including timing, and could be
material to our Consolidated Statements of Operations.
Conference Call/Webcast Information
Dentsply Sirona's management team will host an investor conference call and live
webcast on November 5, 2026 at 4:30 p.m. ET. The live webcast and a presentation
related to the call will be available on the Investors section of the Company's
website at https://investor.dentsplysirona.com.
For those planning to participate on the call, please register at
http://register-conf.media-
server.com/register/BI087bbe14635a47a484497a4e4376efc9. A webcast replay of the
conference call will be available on the Investors section of the Company's
website following the call.
About Dentsply Sirona
Dentsply Sirona is the world's largest diversified manufacturer of professional
dental products and technologies, with over a century of innovation and service
to the dental industry and patients worldwide. Dentsply Sirona develops,
manufactures, and markets a comprehensive solutions offering, including dental
and oral health products as well as other consumable medical devices under a
strong portfolio of world-class brands. Dentsply Sirona's innovative products
provide high-quality, effective and connected solutions to advance patient care
and deliver better and safer dental care. Dentsply Sirona is headquartered in
Charlotte, North Carolina. The Company's shares are listed in the United States
on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more
information about Dentsply Sirona and its products.
Contact Information:
Investors:
Suzanne Hatcher
Investor Relations
[email protected]
Press:
Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
[email protected]
Forward-Looking Statements and Associated Risks
All statements in this Press Release that do not directly and exclusively relate
to historical facts constitute "forward-looking statements." Such statements are
subject to numerous assumptions, risks, uncertainties and other factors that
could cause actual results to differ materially from those described in such
statements, many of which are outside of our control, including those described
in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on
Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports
on Form 10-Q for any subsequent fiscal quarters, and any updating information or
other factors which may be described in the Company's other filings with the
Securities and Exchange Commission (the "SEC"). No assurance can be given that
any result, expectation, belief, goal or plan set forth in any forward-looking
statement can or will be achieved, and readers are cautioned not to place undue
reliance on such statements which speak only as of the date they are made. We do
not undertake any obligation to update or release any revisions to any forward-
looking statement or to report any events or circumstances after the date of
this Press Release or to reflect the occurrence of unanticipated events.
Investors should understand it is not possible to predict or identify all such
factors or risks. As such, you should not consider the risks identified in the
Company's SEC filings to be a complete discussion of all potential risks or
uncertainties associated with an investment in the Company.
DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 836 $ 904 $ 2,6… $ 2,…
sa…
Co…
of 393 463 1,2… 1,…
pr…
so…
Gr… 443 441 1,3… 1,…
pr…
Se…
ge…
and 363 355 1,0… 1,…
ad…
ex…
Re…
and 42 37 131 110
de…
ex…
Go…
and
in… 3 262 3 497
as…
im…
Re…
and
ot… -2 5 67 18
(i…
ex…
Op…
in… 37 -218 84 -2…
(l…
Ot…
in…
and
ex…
In…
ex… 25 23 71 66
net
Ot…
in… -14 -11 -43 -10
net
In…
(l…
be… 26 -230 56 -3…
in…
ta…
Pr…
for 29 198 33 114
in…
ta…
Net
(l… -3 -428 23 -4…
in…
Le…
Net
lo…
at… -1 -1 -2 -1
to
no…
in…
Net
(l…
in…
at… $ -2 $ -427 $ 25 $ -4…
to
De…
Si…
(L…
ea…
per
co…
sh…
at…
to
De…
Si…
Ba… $ -0.… $ -2.… $ 0.12 $ -2…
Di… $ -0.… $ -2.… $ 0.12 $ -2…
We…
av…
co…
sh…
ou…
Ba… 199… 199… 199… 19…
Di… 199… 199… 200… 19…
DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share amounts)
(unaudited)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current Assets:
Cash and cash equivalents $ 195 $ 326
Accounts and notes 605 688
receivable-trade, net
Inventories, net 707 642
Prepaid expenses and other
current 471 367
assets
Total Current Assets 1,978 2,023
Property, plant, and 845 861
equipment, net
Operating lease 126 139
right-of-use assets, net
Identifiable intangible 815 974
assets, net
Goodwill 1,136 1,148
Other noncurrent assets 290 284
Total Assets $ 5,190 $ 5,429
Liabilities and Equity
Current Liabilities:
Accounts payable $ 238 $ 300
Accrued liabilities 706 700
Income taxes payable 58 30
Notes payable and current
portion of 215 313
long-term debt
Total Current Liabilities 1,217 1,343
Long-term debt 1,985 2,015
Operating lease liabilities 87 93
Deferred income taxes 74 94
Other noncurrent 473 544
liabilities
Total Liabilities 3,836 4,089
Total Equity 1,354 1,340
Total Liabilities and $ 5,190 $ 5,429
Equity
DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
Nine Months Ended
Cash flows from operating September 30,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income (loss) $ 23 $ -453
Adjustments to reconcile
net income
(loss) to net cash
provided by (used in)
operating activities:
Depreciation 110 104
Amortization of intangible 136 155
assets
Goodwill asset impairment — 409
Indefinite-lived
intangible asset 3 88
impairment
Deferred income taxes -50 44
Stock-based compensation 25 25
expense
Other non-cash expense 3 13
(Gain) loss on disposal of -7 —
assets
Changes in operating
assets and
liabilities:
Accounts and notes 67 -56
receivable-trade, net
Inventories, net -78 -61
Prepaid expenses and other
current -5 -10
assets
Other noncurrent assets -2 —
Accounts payable -21 -9
Accrued liabilities -61 -66
Income taxes 30 -45
Other noncurrent -2 -4
liabilities
Net cash provided by
operating 171 134
activities
Cash flows from investing
activities:
Capital expenditures -128 -90
Cash received on — 10
derivative contracts
Cash paid on derivative — -9
contracts
Net investment hedge -17 —
settlements
Proceeds from sale of
property, plant, 4 —
and equipment
Other investing activities 6 2
Net cash used in investing -135 -87
activities
Cash flows from financing
activities:
Cash paid for treasury -25 —
stock
Proceeds from 364-day — 435
bridge loan
Repayment of 364-day — -435
bridge loan
Proceeds (repayments) on
short-term 130 -416
borrowings, net
Cash dividends paid -32 -96
Proceeds from long-term — 551
borrowings
Repayments on long-term -225 -3
borrowings
Cash paid for deferred — -13
financing costs
Other financing -6 -4
activities, net
Net cash (used in)
provided by financing -158 19
activities
Effect of exchange rate
changes on cash -9 25
and cash equivalents
Net (decrease) increase in
cash and cash -131 91
equivalents
Cash and cash equivalents
at beginning 326 272
of period
Cash and cash equivalents
at end of $ 195 $ 363
period
Supplemental disclosures
of cash flow
information:
Interest paid, net of
amounts $ 78 $ 65
capitalized
Non-cash investing
activities:
Property, plant and
equipment in $ 37 $ 25
accounts payable at end of
period
Exchange of inventory for
naming and $ — $ 14
other rights
Supplemental Information – Reconciliation of GAAP to Non-GAAP Financial Measures
We supplement the reporting of our financial information determined under
accounting principles generally accepted in the United States ("GAAP") with
certain non-GAAP financial measures, including percentage sales growth in
constant currency; adjusted gross profit; adjusted gross profit as a percent of
net sales ("Adjusted Gross Margin"); adjusted operating income; adjusted
operating income as a percent of net sales ("Adjusted Operating Margin");
adjusted earnings before interest expense, income taxes, depreciation and
amortization ("Adjusted EBITDA"); Adjusted EBITDA as a percent of net sales
("Adjusted EBITDA Margin"); adjusted net income (loss); adjusted earnings (loss)
per diluted share ("Adjusted EPS"); and Free Cash Flow. These non-GAAP financial
measures are used by the Company to measure its performance and management
believes these non-GAAP financial measures provide meaningful information to
assist investors and shareholders in understanding our financial results and
assessing our prospects for future performance. Management believes percentage
sales growth in constant currency and the other adjusted measures described
above are important indicators of our operations because they exclude items that
may not be indicative of or are unrelated to our core operating results and
provide a baseline for analyzing trends in our underlying businesses. Management
uses these non-GAAP financial measures for reviewing the operating results of
reportable business segments and analyzing potential future business trends in
connection with our budget process and bases certain management incentive
compensation on these non-GAAP financial measures.
The Company has defined the non-GAAP measures used by management as follows:
• Constant Currency: reported net sales adjusted for the impact of foreign
currency changes, which is calculated by translating current period net sales
using the comparable prior period's foreign currency exchange rates.
• Adjusted Operating Income and Margin: Adjusted operating income is computed by
excluding the following items from operating income (loss) as reported in
accordance with US GAAP. Adjusted operating margin is calculated by dividing
adjusted operating income by net sales.
◦ Business combination-related costs : costs related to consummating and
integrating acquired businesses, as well as net gains and losses related to
disposed businesses. Costs include the post-acquisition roll-off of fair value
adjustments recorded related to business combinations, except for amortization
expense of purchased intangible assets noted below.
◦ Restructuring-related charges and other costs : costs related to the
implementation of restructuring initiatives, including but not limited to,
severance costs, facility closure costs, and lease and contract termination
costs, as well as related professional service costs associated with these
restructuring initiatives and global transformation activity. Other costs
include gains and losses on the sale of property, legal settlements, executive
separation costs, write-offs of inventory as a result of product
rationalization, and changes in accounting principles recorded within the
period. This category also includes costs related to investigations and
associated legal cases and remediation activities, which primarily include
legal, accounting and other professional service fees, as well as turnover and
other employee-related costs.
◦ Goodwill and intangible asset impairments : include charges related to
goodwill and intangible asset impairments.
◦ Amortization of purchased intangible assets : includes the periodic
amortization expense related to purchased intangible assets, which are recorded
at fair value.
◦ Fair value and credit risk adjustments : include the non-cash mark-to-market
changes in fair value associated with pension assets and obligations, the credit
risk component of hedging instruments, contingent consideration from past
acquisitions, and equity-method investments.
• Adjusted Gross Profit and Margin: gross profit excluding the impact of any of
the above adjustments that affect either net sales or cost of sales. Adjusted
gross margin is calculated by dividing adjusted gross profit by net sales.
• Adjusted Net Income (Loss): net income (loss) as reported in accordance with
US GAAP, adjusted to exclude the items identified above and the related income
tax impacts of those
items, as well as the tax effects of certain significant and discrete tax
adjustments, including benefits and provisions related to changes in realization
of deferred tax assets and tax credit carryforwards, as well as other events
that affect comparability and are not core to our underlying operational
performance.
• Adjusted EBITDA and Margin: in addition to the adjustments described above in
arriving at adjusted net income, adjusted EBITDA is computed by further
excluding any remaining interest expense, net, income tax expense, depreciation
and amortization. Adjusted EBITDA margin is calculated by dividing adjusted
EBITDA by net sales.
• Adjusted Earnings (Loss) Per Diluted Share: computed by dividing adjusted
earnings (loss) attributable to Dentsply Sirona stockholders by the diluted
weighted average number of common shares outstanding.
• Free Cash Flow: net cash provided by operating activities minus capital
expenditures during the same period.
Because non-GAAP financial measures are not standardized, it may not be possible
to compare these financial measures with other companies' non-GAAP financial
measures having the same or similar names. These adjusted financial measures
should not be considered in isolation or as a substitute for the most directly
comparable GAAP financial measures. These non-GAAP financial measures are an
additional way of viewing aspects of our operations that, when viewed with our
GAAP results and the reconciliations to corresponding GAAP financial measures
below, provide a more complete understanding of our business. We strongly
encourage investors and shareholders to review our financial statements and
publicly-filed reports in their entirety and not to rely on any single financial
measure.
The following reconciles the non-GAAP financial measures discussed above with
the most directly comparable GAAP financial measures. The weighted-average
diluted shares outstanding used in the calculation of adjusted net earnings per
diluted share are the same as those used in the calculation of reported net
earnings per diluted share for the respective period. The weighted-average
diluted shares outstanding used in the calculation of adjusted net loss per
diluted share excludes potential dilutive common shares.
DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)
Beginning in fiscal year 2026, the Company updated its definition of Adjusted
Net Income (Loss), a non-GAAP financial measure, to include adjustments for
certain significant and discrete tax items, including benefits and provisions
related to changes in the realization of deferred tax assets and tax credit
carryforwards, as well as other tax‑related items that affect comparability and
are not considered part of the Company's core operational performance. Prior-
period information below has been updated to conform to current period
presentation. A reconciliation of selected items as reported in the Condensed
Consolidated Statements of Operations to adjusted Non-GAAP financial statements
items are as follows:
Net
T… (L…
M… In… Dil…
E… Pro… At… (Lo…
S… for to Ear…
3… Gr… Op… Inc… De… per
2… Pr… In… Tax… Si… Sha…
──────────────────────────────────────────────────────────────────────────────
R… $ 443 $ 37 $ 29 $ -2 $ -0…
R…
p… 52… % 4.4 %
n…
s…
N…
A…
A…
of
P… 12 46 11 35 0.…
I…
A…
R…
C…
a… 1 10 2 8 0.…
O…
C…
(…
G…
a…
I… — 3 1 2 0.…
A…
I…
B…
C… — — — — —
C…
F…
V…
a… — -1 — -1 —
C…
R…
A…
I…
T… — — -17 17 0.…
A…
(…
A… $ 456 $ 95 $ 26 $ 59 $ 0.…
A…
p… 54… % 11… %
n…
s…
W…
a…
c…
s…
o…
u…
in
c… 19…
d…
G…
n…
l…
p…
c…
s…
W…
a…
c…
s…
o…
u…
in
c… 20…
d…
N…
n…
i…
p…
c…
s…
(…
R…
C…
a…
O…
C…
i…
c…
f…
r…
a…
a…
t…
n…
g…
E…
s…
p…
o…
by
a
$9
c…
in
e…
f…
t…
2…
r…
p…
T…
a…
a…
on
a
p…
b…
(…
I…
T…
A…
i…
a…
f…
i…
v…
a…
f…
t…
U…
of
$…
L…
of
$…
a…
S…
of
$2
a…
d…
v…
a…
f…
G…
of
$…
a…
w…
o…
v…
t…
a…
Percentages are based on actual values and may not reconcile due to rounding.
Net
T… (L…
M… In… Di…
E… Pr… At… (L…
S… Op… for to Ea…
3… Gr… (L… In… De… per
2… Pr… In… Ta… Si… Sh…
──────────────────────────────────────────────────────────────────────────────
R… $ 441 $ -2… $ 198 $ -4… $ -2…
R…
p… 48… % (2… %)
n…
s…
N…
A…
A…
of
P… 33 56 15 41 0.…
I…
A…
R…
C…
a… 1 17 -3 20 0.…
O…
C…
(…
G…
a…
I… — 262 -1 263 1.…
A…
I…
B…
C… — 2 1 1 0.…
C…
I…
T… — — -1… 186 0.…
A…
(…
A… $ 475 $ 119 $ 24 $ 84 $ 0.…
A…
p… 52… % 13… %
n…
s…
W…
a…
c…
s…
o…
u…
in
c… 19…
d…
G…
n…
l…
p…
c…
s…
W…
a…
c…
s…
o…
u…
in
c… 20…
d…
N…
n…
i…
p…
c…
s…
(…
R…
C…
a…
O…
C…
i…
$5
in
c…
f…
t…
n…
g…
E…
s…
$4
in
c…
f…
v…
r…
a…
r…
to
e…
s…
$4
in
e…
s…
c…
a…
v…
o…
c…
A…
a…
on
a
p…
b…
(…
I…
T…
A…
i…
a…
f…
d…
v…
a…
f…
L…
of
$…
a…
w…
i…
v…
a…
f…
G…
of
$5
a…
S…
of
$…
a…
o…
v…
t…
a…
Percentages are based on actual values and may not reconcile due to rounding.
DENTSPLY SIRONA INC. AND SUBSIDIARIES
(in millions, except per share amounts and percentages)
(unaudited)
Reconciliations of reported net loss attributable to Dentsply Sirona to adjusted
EBITDA and margin are as follows:
Three Months Ended
September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net loss attributable to $ -2 $ -427
Dentsply Sirona
Interest expense, net 25 23
Provision for income taxes 29 198
Depreciation(1) 36 36
Amortization of intangible 46 56
assets
Restructuring-related charges
and other 10 17
costs
Goodwill and intangible asset 3 262
impairments
Business combination-related
costs and — 2
fair value adjustments
Fair value and credit risk -1 —
adjustments
Adjusted EBITDA $ 146 $ 167
Net sales $ 836 $ 904
Adjusted EBITDA margin 17.3 % 18.4 %
(1) Excludes those depreciation-related amounts which were included as part of
the business combination-related adjustments and Restructuring-related charges
and other costs.
Percentages are based on actual values and may not reconcile due to rounding.
A reconciliation of free cash flow for the three months ended September 30, 2026
and 2025 is as follows:
Three Months Ended
September 30, 2026 2025
───────────────────────────────────────────────────────────────────────
Net cash provided by operating $ 32 $ 79
activities
Capital expenditures -32 -39
Free cash flow $ — $ 40